title: Pharmacological characterization of the contractile effects of galanin (1-29)-NH2, galantide and galanin (1-14)-(alpha-aminobutyric acid8)scyliorhinin-I in the rat gastric fundus.
abstract: Porcine galanin (1-29)-NH2, galantide (M15) and galanin (1-14)-(alpha-aminobutyric acid8)-scyliorhinin-I used in concentrations of 300, 1,000 and 3,000 nM respectively caused contractions of rat fundus strips. The contractile responses to galanin(1-29)-NH2 were not modified by atropine (10 microM), guanethidine (10 microM), naloxone (1 microM), a mixture of propranolol (10 microM) and phentolamine (10 microM), indomethacin (10 microM), a mixture of mepyramine (10 microM) and cimetidine (10 microM), saralasin (10 microM), and spantide (100 microM). The effects of M15 and galanin(1-14)-(alpha-aminobutyric acid8)-scyliorhinin-I were significantly decreased by atropine for 36 and 18% and by spantide for 37 and 26% respectively. Indomethacin inhibited the muscle response to M15 without influence on the galanin (1-14)-(alpha-aminobutyric acid8)-scyliorhinin-I-induced action. These results support findings that galanin (1-29)-NH2 contracts rat gastric fundus strips by stimulating specific receptors localized on the surface of smooth muscle cells. M15 and galanin(1-14)-(alpha-aminobutyric acid8)-scyliorhinin-I seem to contract smooth muscles not only by acting at galanin receptors, but by interacting with muscarinic or tachykinin receptors or modulating the release of acetylcholine and substance P. Diltiazem (EC50 825 nM), dantrolene (EC50 30.2 microM) and the phospholipase C inhibitors U-73122 (EC50 549 microM) and U-73343 (EC50 751 microM) lowered the contraction to galanin(1-29)-NH2 in a concentration-dependent manner. These observations imply that though the extracellular Ca2+ influx plays a major role in the action of galanin(1-29)-NH2, the release of Ca2+ ions from the intracellular stores contributes to the response of smooth muscles of galanin(1-29) NH2. Norepinephrine (30, 60, 100 and 300 nM) concentration-dependently reduced the Emax to galanin (1-29)-NH2 and reduced the slopes of the concentration-contraction curves, without a notable change in EC50. Pertussis toxin pre-treatment (10 and 30 mg/kg intravenous [i.v.]), 120 h before the experiment, notably increased the maximal response of the rat gastric fundus to galanin(1-29)-NH2, without a significant change in the properties of the concentration-contraction curves (EC50, slopes). The observations may suggest that pertussis toxin-sensitive GTP-binding proteins are involved in the modulation of the excitatory effects of galanin(1-29)-NH2 in the rat gastric fundus.
authors.affiliation: Department of Pharmacology, Medical University of Gdansk, Gdansk-Wrzeszcz, Poland.
authors.forename: R
authors.initials: R
authors.lastname: Korolkiewicz
authors.forename: W
authors.initials: W
authors.lastname: Sliwiński
authors.forename: Z
authors.initials: Z
authors.lastname: Konstański
authors.forename: P
authors.initials: P
authors.lastname: Rekowski
authors.forename: A
authors.initials: A
authors.lastname: Halama-Borowiec
authors.forename: A
authors.initials: A
authors.lastname: Szyk
authors.forename: J
authors.initials: J
authors.lastname: Emerich
authors.forename: K Z
authors.initials: KZ
authors.lastname: Korolkiewicz
mesh_terms: D000109:Acetylcholine / Q000378:metabolism; D000700:Analgesics / Q000494:pharmacology; D000818:Animals; D015220:Calcium Channels / Q000378:metabolism; D004305:Dose-Response Relationship, Drug; D005260:Female; D019004:Galanin / Q000031:analogs & derivatives* / Q000037:antagonists & inhibitors / Q000494:pharmacology*; D005748:Gastric Fundus / Q000187:drug effects*; D006633:Histamine Antagonists / Q000494:pharmacology; D007213:Indomethacin / Q000494:pharmacology; D008297:Male; D009119:Muscle Contraction / Q000187:drug effects; D009130:Muscle, Smooth / Q000187:drug effects*; D009638:Norepinephrine / Q000494:pharmacology; D037342:Pertussis Toxin; D051381:Rats; D017208:Rats, Wistar; D044088:Receptors, Galanin; D011964:Receptors, Gastrointestinal Hormone / Q000187:drug effects* / Q000378:metabolism; D012519:Sarcoplasmic Reticulum / Q000187:drug effects / Q000378:metabolism; D013373:Substance P / Q000031:analogs & derivatives* / Q000037:antagonists & inhibitors / Q000378:metabolism / Q000494:pharmacology; D013565:Sympatholytics / Q000494:pharmacology; D013566:Sympathomimetics / Q000494:pharmacology; D010566:Virulence Factors, Bordetella / Q000494:pharmacology
chemical_list: D000700:Analgesics; D015220:Calcium Channels; D006633:Histamine Antagonists; D044088:Receptors, Galanin; D011964:Receptors, Gastrointestinal Hormone; D013565:Sympatholytics; D013566:Sympathomimetics; D010566:Virulence Factors, Bordetella; C103759:galanin(1-14)-(aminobutyrate)SCY-I; C074975:galantide; D013373:Substance P; D019004:Galanin; D037342:Pertussis Toxin; D000109:Acetylcholine; D009638:Norepinephrine; D007213:Indomethacin